Searchable abstracts of presentations at key conferences in endocrinology

ea0090p328 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

How do diabetes-related ketoacidosis outcomes compare between hospitals? Results from a quality improvement project

Hallum Abigail , Narendran Arjun , Dalzell Joseph , Needs Catherine , George Arun , Narendran Parth , De Parijat , Lubina Solomon Alexandra , Krishnasamy Senthil , Raghavan Rajeev , Working Group Dekode

Background: The appropriate and timely management of diabetes-related ketoacidosis (DKA) has important implications for patient outcomes. Despite the availability of national management guidelines to promote standardised care, we do not know if there are differences in DKA outcomes and complications between hospitals.Aim: To assess for differences in DKA outcomes and treatment complications between hospitals.Methods: This retrospec...

ea0094p215 | Metabolism, Obesity and Diabetes | SFEBES2023

Trends in the rate of complications and outcomes in DKA management following modifications in JBDS national guidelines-Results from DEKODE study

Abraham Anu , Solomon Alexandra , Birchenough Amy , Cheung Jason , Rengarajan Lakshmi , Hebbar Meghna , Ali Karamat Muhammad , Ahmed Nabeel , De Parijat , Soghal Shamanth , Working group DEKODE , Falowo Durodoluwa

Introduction: Joint British Diabetes Societies Inpatient (JBDS-IP) recommended reducing fixed-rate intravenous insulin infusion (FRIII) rate to 0.05units/kg/hr when blood glucose falls <14 mmol/l to avoid hypoglycaemia during diabetes-related ketoacidosis (DKA).Aim: We studied the impact of guideline change on complications and outcomes of DKA.Methods: We included all DKA episo...

ea0099oc12.4 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024

Characteristics and outcomes of DKA in people taking SGLT2 inhibitors: DEKODE study

Mathur Nitish , Sharma Angelica , Philip Nevil , Rengarajan Lakshmi , Bomphrey Lucy , Abraham Anu , Saraf Sanjay , Dhatariya Ketan , Kempegowda Punith , Working Group Dekode

Background: Although SGLT2 inhibitors (SGLT2-i) have revolutionised the management of diabetes, they are associated with an increased risk of developing diabetic ketoacidosis (DKA). However, there remains a paucity of evidence about the risk factors, management, and outcomes of DKA episodes associated with SGLT2-i therapy. Improved understanding of these factors in order to optimise education, minimise risk, and improve outcomes of DKA episodes in individuals receiving SGLT2-i...